NEW YORK (GenomeWeb News) – BioView and ScreenCell today announced a deal to develop a circulating tumor cell analysis technology.

The agreement seeks to combine ScreenCell's technology for isolating rare cells that may have prognostic and predictive value in cancer and BioView's scanning platform, which provides automated imaging and analysis solutions for rare cell and circulating tumor cell detection.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.